7LBA Safety, activity, and response durability assessment of single agent rovalpituzumab tesirine, a delta-like protein 3 (DLL3)-targeted antibody drug conjugate (ADC), in small cell lung cancer (SCLC). (September 2015) - Pietanza, M.C.; Spigel, D.; Bauer, T.M.; Ready, N.E.; Glisson, B.S.; Morgensztern, D.; Robert, F.; Salgia, R.; Kochendorfer, M.; Patel, M.; Strickland, D.K.; Govindan, R.; et al.